You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

133 Results
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
ODB - General Benefit
    dexamethasone
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Funding:
Exceptional Access Program
    acalabrutinib - In Combination with Bendamustine and Rituximab for Mantle Cell Lymphoma, based on criteria
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Maintenance Treatment - Lymphoma
Mar 2026
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin
Intent: Palliative
Funding:
New Drug Funding Program
    Brentuximab Vedotin - Relapsed or Refractory Hodgkin Lymphoma
Mar 2026
Guidelines and Advice
Status: Current
ID: GL 4-11
Version: 2
Updated
Mar 2026
Drug
Other Name(s): Velcade®
Updated
Apr 2026
Drug
Other Name(s): Treanda®
Updated
Apr 2026
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Intent: Neoadjuvant, Adjuvant
Updated
Apr 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Updated
Apr 2026
Regimen
Cancer Type:
Head and Neck, 
Nasopharynx
Intent: Palliative
Updated
Apr 2026
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Intent: Palliative
New
Apr 2026

Pages